Citius Oncology enters distribution services agreement with Cardinal Health

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals,(CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, announced that it has entered into a distribution services agreement with Cardinal Health (CAH). This agreement is designed to help provide access to LYMPHIR, an innovative immunotherapy FDA-approved for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, in support of its anticipated U.S. commercial launch. “This agreement marks a key step forward in our launch readiness efforts,” said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. “Cardinal Health’s proven distribution capabilities will help ensure LYMPHIR reaches healthcare providers and patients efficiently and reliably, as we work to build a robust commercial distribution network.”